initial public offerings (IPOs) trading on American exchanges

Thursday, September 7, 2017

Adaptimmune Therapeutics (ADAP) : GSK exercises option over SPEAR T-cell therapy program

Adaptimmune Therapeutics announces that GlaxoSmithKline (GSK) has exercised its option under 2014 license agreement
Adaptimmune will receive up to ~$61 million from GSK over the course of the transition period.
  • This includes development milestones of up to ~$23 million and the option payment of ~$38 million, which also allows GSK to nominate two additional targets following completion of the transition.
  • Successful continuation of development and subsequent commercialization of NY-ESO would trigger additional payments for development milestones, tiered sales milestones, and mid-single to low double-digit royalties on worldwide net sales.
  • Co states, "From a financial perspective, this option exercise extends our cash runway into 2020. We anticipate the transition of NY-ESO to GSK to be completed over the coming months, after which we will focus our clinical resources on delivery and execution from our wholly-owned assets MAGE-A4, MAGE-A10, and AFP."
** charts before  ** 


No comments:

Post a Comment